Skip to main content
. 2021 Aug 14;10(8):1030. doi: 10.3390/pathogens10081030

Table 1.

Type of vaccine candidates with developers and stage of clinical evaluation.

Type of Candidate Vaccine Developer (Some Examples) Stage of Clinical Evaluation
DNA Zydus Cadila
Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical
AnGes + Takara Bio + Osaka University
CTRI/2020/07/026352 (phase 2/3)
NCT04642638 (phase 2/3)
NCT04655625 (phase 3)
mRNA BioNTech/Fosun, Pharma/Pfizer (BNT162b2)
Moderna (mRNA-1273)
NCT04368728 (Authorized)
NCT04760132 (Authorized)
Inactivated vaccine Sinovac Research and Development Co, Ltd.
Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products
NCT04756830 (Authorized)
NCT04863638 (Authorized)
Live attenuated vaccine Codagenix/Serum Institute of India
Meissa Vaccines, Ins.
NCT04619628 (Phase 1)
NCT04798001 (Phase 1)
Recombinant protein subunit vaccine Novavax
Sanofi Pasteur + GSK
Instituto Finlay de Vacunas
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “vector”
Center for Genetic Engineering and Biotechnology (CIGB)
NCT04611802 (phase 3)
PACTR202011523101903 (phase 3)
RPCEC00000354 (phase 3)
NCT04780035 (phase 3)
RPCEC00000359
Viral vectors-based vaccines AstraZeneca + University of Oxford
CanSino Biological Ins./Beijing Institute of Biotechnology
Gamaleya Research Institute; Health Ministry of the Russian Federation
Janssen Pharmaceutical
NCT04760132 (Authorized)
NCT045226990 (Authorized)
NCT04530396 (Authorized)
NCT04505722 (Authorized)